ASTELLAS PHARMA

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 2005-01-01

Employees: -

Market Cap: $22.5B

Website: https://www.astellas.com/

Clinical Trials

A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride When Given Together to Healthy Subjects

Phase 1

Completed

Conditions: Healthy
Pharmacokinetics of ASP1941

Interventions: Drug: ASP1941
Drug: pioglitazone hydrochloride

First Posted Date: 2010-03-18

Last Posted Date: 2010-04-16

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 64

Registration Number: NCT01088919

ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis

Phase 1

Completed

Conditions: Anemia
Hemodialysis
Renal Impairment

Interventions: Drug: roxadustat

First Posted Date: 2010-03-10

Last Posted Date: 2024-10-30

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 12

Registration Number: NCT01083888

A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: ipragliflozin
Drug: Placebo
Drug: Metformin

First Posted Date: 2010-02-19

Last Posted Date: 2024-11-06

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 412

Registration Number: NCT01071850

Locations: 🇺🇸
CSRA Partners in Health, Inc., Augusta, Georgia, United States
🇺🇸
Atlanta Vascular Research Foundation, Atlanta Cardiology & Primary Care P.C., Tucker, Georgia, United States
🇮🇳
Bride, Bharti Hospital, Karnal, India

and more 56 locations

Liver Transplant European Study Into the Prevention of Fungal Infection

Phase 3

Completed

Conditions: Liver Transplantation
Mycoses

Interventions: Drug: micafungin
Drug: fluconazole
Drug: liposomal amphotericin B
Drug: caspofungin

First Posted Date: 2010-01-28

Last Posted Date: 2024-11-18

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 350

Registration Number: NCT01058174

A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis

Phase 3

Completed

Conditions: Chronic Kidney Disease
Renal Dialysis
Renal Insufficiency

Interventions: Drug: ASP1585
Drug: Sevelamer hydrochloride

First Posted Date: 2010-01-27

Last Posted Date: 2015-05-04

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 110

Registration Number: NCT01057407

A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes Patients

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: placebo
Drug: ipragliflozin

First Posted Date: 2010-01-27

Last Posted Date: 2024-11-04

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 130

Registration Number: NCT01057628

A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: ipragliflozin

First Posted Date: 2010-01-22

Last Posted Date: 2024-11-11

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 182

Registration Number: NCT01054092

A Study of YM178 in Subjects With Symptoms of Overactive Bladder

Phase 3

Completed

Conditions: Urinary Bladder, Overactive

Interventions: Drug: YM178
Drug: Placebo
Drug: tolterodine ER

First Posted Date: 2010-01-07

Last Posted Date: 2024-10-31

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 1126

Registration Number: NCT01043666

A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: YM155
Drug: Docetaxel

First Posted Date: 2009-12-24

Last Posted Date: 2013-09-18

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 101

Registration Number: NCT01038804

Locations: 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇧🇪
Sint-Augustinus GZA Ziekenhuizen, Wilrijk, Belgium
🇺🇸
Bay Area Cancer Research Group, Pleasant Hill, California, United States

and more 27 locations

Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects

Completed

Conditions: Bladder Function

Interventions: Procedure: cystometry
Procedure: polysomnography

First Posted Date: 2009-12-09

Last Posted Date: 2011-03-07

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 26

Registration Number: NCT01029015

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy